Pimobendan is a veterinary medication used primarily to manage congestive heart failure in dogs, especially in conditions such as dilated cardiomyopathy and degenerative mitral valve disease. It was developed in the late 20th century by Boehringer Ingelheim as part of efforts to create more effective heart failure treatments with fewer limitations than traditional drugs. Initially investigated for use in human medicine during the 1990s, its development shifted to veterinary applications after mixed outcomes in human trials. Pimobendan was later introduced in Europe and marketed under the brand name Vetmedin, gaining recognition for its unique dual mechanism of action as both a calcium sensitizer and a phosphodiesterase III inhibitor. A major milestone occurred in 2007 when it was approved by the U.S. Food and Drug Administration for the treatment of congestive heart failure in dogs, which led to widespread global adoption.
BRAND NAMES
Vetmedin
Cardisure
Pimobend
Pimocard
Cardimed
Pimotab
MECHANISM OF ACTION
Pimobendan works as a calcium sensitizer and a phosphodiesterase III (PDE3) inhibitor. It increases the heart muscle’s response to calcium, improving the strength of contraction without greatly increasing oxygen demand. At the same time, it causes vasodilation, which reduces the resistance against which the heart must pump.
PHARMACOKINETICS
Absorption
Pimobendan is well absorbed after oral administration, with high bioavailability in dogs. Food can slightly reduce the rate but not the extent of absorption. It is rapidly absorbed from the gastrointestinal tract and is then converted in the liver to its active metabolite, which contributes significantly to its therapeutic effect.
Distribution
Pimobendan is widely distributed throughout the body after absorption. It is highly protein-bound in plasma, which helps maintain its circulation in the bloodstream. The drug and its active metabolite distribute well into cardiac tissue, where they exert their therapeutic effects on the heart and blood vessels.
Metabolism
Pimobendan is extensively metabolized in the liver to its active metabolite, O-desmethyl-pimobendan. This metabolite has strong pharmacological activity and contributes significantly to the drug’s effects. The metabolism mainly occurs through hepatic enzymatic pathways.
Elimination
Pimobendan and its active metabolite are mainly eliminated through the feces via biliary excretion, with a smaller portion excreted in urine. The elimination half-life supports twice-daily dosing in most veterinary patients, especially dogs.
PHARMACODYNAMICS
Pimobendan produces a positive inotropic effect by increasing the sensitivity of cardiac muscle to calcium, resulting in stronger heart contractions without significantly increasing myocardial oxygen consumption. It also inhibits phosphodiesterase III (PDE3), leading to vasodilation of both arteries and veins, which reduces preload and afterload. Together, these actions improve cardiac output, decrease cardiac workload, and help manage signs of congestive heart failure.
ADMINISTRATION
Pimobendan is administered orally, usually in tablet form, and is given approximately 1 hour before feeding for optimal absorption. It is commonly prescribed twice daily at 12-hour intervals in dogs with congestive heart failure. The dosage is weight-based and should be strictly followed as directed by a veterinarian. The tablets should not be crushed or split unless specifically instructed.
DOSAGE AND STRENGTH
Pimobendan is commonly given to dogs at a dose of 0.25–0.3 mg/kg orally every 12 hours, usually about one hour before food. The dose is adjusted based on body weight and severity of heart disease. It is available in tablet strengths such as 1.25 mg, 2.5 mg, 5 mg, and 10 mg, allowing precise dosing as prescribed by a veterinarian.
DRUG INTERACTIONS
Pimobendan should be used cautiously with other cardiovascular drugs such as ACE inhibitors, diuretics, and positive inotropes, as these are often used together in heart failure therapy and may have additive effects. Concurrent use with calcium channel blockers or beta-blockers may reduce its effectiveness due to opposing cardiac actions. It should be used carefully with other vasodilators or drugs affecting blood pressure to avoid excessive hypotension.
FOOD INTERACTIONS
Food may slightly slow the absorption of pimobendan, but it does not significantly reduce its overall effectiveness. For optimal results, it is usually given about one hour before meals. However, if needed, it can still be administered with food, as the clinical effect is not greatly affected.
CONTRAINDICATIONS
Pimobendan is contraindicated in dogs with hypertrophic cardiomyopathy (HCM) or other conditions where increased cardiac contractility may worsen obstruction of blood flow. It should also be avoided in cases of severe aortic stenosis or other outflow tract obstructions. The drug is not recommended in animals with known hypersensitivity to pimobendan or its components.
SIDE EFFECTS
Decreased appetite
Lethargy
Increased heart rate (tachycardia)
Coughing
Rare arrhythmias
OVER DOSAGE
Overdose of pimobendan can cause excessive cardiac stimulation leading to tachycardia, hypotension, and possible arrhythmias. Gastrointestinal signs like vomiting and diarrhea may also occur. In severe cases, it may worsen heart function.
TOXICITY
Pimobendan has a relatively wide safety margin in dogs, but toxicity can occur at high doses or with prolonged overdose. Toxic effects mainly involve excessive cardiovascular stimulation, leading to tachycardia, arrhythmias, hypotension, and potential worsening of heart failure. Gastrointestinal signs such as vomiting and diarrhea may also be seen. Severe toxicity is uncommon and is managed with supportive and symptomatic veterinary care.
